Insulet Flags Manufacturing Issue Affecting 7M Insulin Pods

Dow Jones
05/27

By Katherine Hamilton

 

Insulet is voluntarily correcting certain insulin pod medical devices due to a manufacturing issue that could result in the pods not delivering enough insulin.

The maker of insulin delivery pods for people with diabetes said its Omnipod 5, Omnipod DASH and Omnipod Insulin Management System pods are all part of the correction.

Some pods from specific lots may have a small tear in the tubing just above the skin. If this occurs, insulin could leak outside the pod and result in under-delivery of insulin to the person wearing the pod.

About 7 million pods are included within the scope of the correction, roughly 60% of which have been consumed or are expired. The pods affected by the correction represent about 8.5% of Insulet's production of Omnipods in 2025.

Shares fell 7.5% to $141.50 in after-hours trading Tuesday. Through the close, the stock was down 46% this year.

People using an affected pod may notice wetness on their skin or pod adhesive, or they could detect the smell of insulin, Insulet said. In some cases, the issue may be difficult to detect and go unnoticed.

If patients aren't receiving enough insulin, it could result in high blood glucose levels and potentially lead to diabetic ketoacidosis.

Globally, there have been 24 reports of serious adverse events. No deaths have been reported.

This correction is separate from an earlier voluntary correction Insulet issued in March on certain Omnipod 5 pods in the U.S. It includes certain pod lots distributed in the U.S. and international markets.

Insulet said it identified the cause of the issue and is strengthening its in-process monitoring and quality controls. It is also communicating with affected customers to help them get replacement pods at no cost.

Insulet has enough supply to replace affected pods and doesn't anticipate any disruption to product availability, it said.

Customers should visit Check Pod to confirm whether their pod lot number is included in the correction, Insulet said.

 

Write to Katherine Hamilton at katherine.hamilton@wsj.com

 

(END) Dow Jones Newswires

May 26, 2026 16:41 ET (20:41 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10